Unit
- Opioid receptors: Three main types (mu, kappa, delta) mediate the effects of opioids. Mu receptors are primarily responsible for analgesia, euphoria, and respiratory depression. Chronic activation leads to neuroadaptive changes that underlie tolerance and dependence.
- Dopamine reward pathway: Opioids increase dopamine release in the nucleus accumbens, reinforcing drug-seeking behavior. Over time, the brain's reward threshold increases, requiring higher doses to achieve the same effect. This mechanism is central to the development of addiction.
- Neuroplasticity in addiction: Long-term opioid use alters synaptic strength in brain regions involved in learning and memory, such as the prefrontal cortex and amygdala. These changes contribute to compulsive drug use and craving even after prolonged abstinence.
- Withdrawal syndrome: When opioids are discontinued, the brain's compensatory mechanisms produce a withdrawal syndrome characterized by anxiety, muscle aches, diarrhea, and intense cravings. Understanding withdrawal is critical for managing detoxification and induction onto medication-assisted treatment.
- Genetic factors: Genetic variations in opioid receptor genes and metabolic enzymes (e.g., CYP2D6) influence individual susceptibility to opioid use disorder. Family studies show heritability estimates of 30-60%, highlighting the importance of personalized risk assessment.
- Environmental triggers: Stress, trauma, and social environment play significant roles in the initiation and maintenance of opioid use. Chronic stress activates the hypothalamic-pituitary-adrenal axis, which interacts with the reward system to promote relapse.
- Stages of addiction: The addiction cycle includes binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation. Each stage involves distinct neurobiological circuits and presents opportunities for targeted intervention.
- Brain imaging insights: Functional imaging studies show reduced prefrontal cortex activity in individuals with opioid use disorder, impairing impulse control and decision-making. These findings support the use of cognitive training and behavioral therapies to strengthen executive function.
- Endogenous opioid system: The body produces naturally occurring opioids called endorphins that modulate pain and reward. Exogenous opioids hijack this system, leading to dysregulation of endogenous opioid release. Understanding this interaction helps explain why opioid withdrawal can cause heightened pain sensitivity and emotional distress.
- Psychiatric comorbidity: Opioid use disorder frequently co-occurs with depression, anxiety, and post-traumatic stress disorder. These conditions share overlapping neurocircuitry involving the amygdala and prefrontal cortex. Integrated treatment that addresses both substance use and mental health improves outcomes and reduces relapse risk.
- Impact on pain processing: Chronic opioid use alters the brain's pain processing pathways, leading to opioid-induced hyperalgesia. This condition causes increased sensitivity to pain and can complicate pain management. Clinicians must differentiate between tolerance, dependence, and hyperalgesia when treating patients on long-term opioid therapy.
Terminology
- Agonist
- A substance that binds to a receptor and produces a biological response. For example, methadone is a full mu-opioid receptor agonist used in medication-assisted treatment.
- Antagonist
- A substance that binds to a receptor but blocks the biological response. Naltrexone is an opioid receptor antagonist that prevents opioids from producing euphoria or sedation.
- Partial agonist
- A substance that binds to a receptor and produces a submaximal response. Buprenorphine is a partial mu-opioid receptor agonist, providing lower risk of respiratory depression.
Regulatory Note
Regulation: The Controlled Substances Act classifies opioids into schedules based on medical use and abuse potential. Schedule II drugs like oxycodone have high abuse potential but accepted medical use, while Schedule V drugs like codeine-containing cough syrups have lower abuse potential.
21 U.S.C. § 812
Quick Revision
- Opioid addiction involves neuroadaptations in the reward, stress, and executive control systems.
- Genetic and environmental factors jointly influence vulnerability to opioid use disorder.
- Understanding the neurobiology guides selection of pharmacotherapy and behavioral interventions.
- Regulatory classification of opioids informs prescribing practices and abuse prevention.